Israel - English - Ministry of Health
Approval for Printing
Approved for Printing
Approved for Printing
New draft required
Each 1000 ml contains:
Water for injection to
High caloric carbohydrate infusion, (in a minimal volume
of water), Hypoglycemia.
The dosage depends on age, weight and clinical condi-
tion of the patient.
Glucose 20 %: Up to 35 ml/kg body weight/day
Glucose 50 %: Up to 14 ml/kg body weight/day
Glucose 20 %: Up to 2.5 ml/kg bw/h or
(for 70 kg patient) up to 58 drops/min = 175 ml/h
Glucose 50 %: Up to 1.0 ml/kg bw/h or
(for 70 kg patient) up to 23 drops/min = 70 ml/h.
For patients in a markedly depleted nutritional state, the
above drop/flow rates have to be reduced accordingly.
Insulin induced hypoglycemia:
Determine blood glucose before injecting dextrose.
According to individual requirements.
Route of administration
I.V. via a central venous catheter.
For total parenteral nutrition Glucose Injection is admin-
istered by slow intravenous infusion (a) after admixture
with amino acid solutions via an indwelling catheter
with the tip positioned in a large central vein, preferably
the superior vena cava, or (b) after dilution with sterile
water for injection. Dosage should be adjusted to meet
individual patient requirements.
In diabetic come while blood sugar is excessively high.
Do not use concentrated solutions when intracranial or
intraspinal hemorrhage is present, in the presence of
delirium tremens in dehydrated patients, or in patients
with glucose-galactose malabsorption syndrome.
Glucose solutions I.V. can cause fluid or solute over load
resulting in dilution of serum electrolyte concentrations,
overhydration, congested states or pulmonary edema.
Hypertonic dextrose solutions may cause thrombosis if
infused via peripheral veins, therefore, administer slowly
via a central venous catheter.
patients with subclinical or overt diabetes mellitus or
It has been suggested that glucose solution should not
be used after acute ischaemic strokes as hyperglycaemia
has been implicated in increasing cerebral ischaemic
brain damage and in impairing recovery.
Rapid administration of hypertonic solutions may pro-
duce significant hyperglycemia or hyperosmolar syn-
drome, especially in patients with chronic uremia or car-
Category C. safety for use during pregnancy has not been
established. Use only when clearly needed and when the
potential benefits outweigh the potential hazards to the
Directions for Use
B. Braun Melsungen AG · 34209 Melsungen, Germany
20 %, 50 % w/v
Projekt14:Layout 1 06.09.2011 10:15 Uhr Seite 1
Use with caution in infants of diabetic mothers, except
as may be indicated in hypoglycemic neonates.
Glucose infusions should not be administered through
the same infusion equipment, simultaneously, before or
after an administration of blood, because of the possibil-
ity of pseudo-agglutination.
This fluid should only be administered with great care to
patients with diabetes mellitus or renal insufficiency.
Clinical supervision should include regular checks of
blood glucose level, serum electrolytes and water bal-
Electrolytes are to be supplemented as required. Caution
is to be exercised in patients with hyponatremia.
No other medication or substance should be added to
this fluid, unless it is known to be compatible. Not suit-
able for osmotherapy.
Hyperglycemia and glycosuria may be functions of rate
of administration or metabolic insufficiency. To minimize
these conditions, slow the infusion rate, monitor blood
and urine glucose; if necessary, administer insulin. When
concentrated Glucose infusion is abruptly withdrawn,
administer 5 % or 10 % Glucose to avoid reactive hypo-
thrombosis occurs during administration, stop injection
When a concentrated Glucose infusion is abruptly with-
drawn, it is advisable to follow with the administration
of 5 % or 10 % Glucose injection to avoid rebound hypo-
receiving corticosteroids or corticotrophin.
Significant hyperglycemia, hyperosmolar syndrome and
glycosuria may occur with too rapid administration of
The product must not be used beyond the expiry date
stated on the labeling.
Do not store above 25 °C.
Glucose 20 %:
500 ml and 1000 ml bottles
Glucose 50 %:
500 ml plastic bottles
50 ml glass vial
20 ml Mini Plasco® ampoules
Glucose 20 %: 137-53-27992-00
Glucose 50 %: 119-08-25555-11, 134-97-25555-00
Lapidot Medical Import and Marketing Ltd.
8 Hashita st., Caesarea Industrial Zone 38900
The format of this leaflet was determined by the Ministry
of Health and its content was checked and approved in
B. Braun Melsungen AG
Projekt14:Layout 1 06.09.2011 10:15 Uhr Seite 2